Zolgensma ‘Lottery’ Attacked From All Sides
Fears It Could Damage Pharma Industry’s Reputation
An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.
You may also be interested in...
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.